Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23874229 | 1.00 | ADORA2A (0.34) | ADORA2ASLC5A1ADORA2B | |
| SCHEMBL25169864 | 1.00 | ADORA2A (0.34) | ADORA2ASLC5A1ADORA2B | |
| SCHEMBL23859569 | 0.79 | ADORA2A (0.41) | ADORA2A | |
| SCHEMBL23859382 | 0.79 | ADORA2A (0.38) | ADORA2ASLC5A1 | |
| SCHEMBL23859380 | 0.79 | ADORA2A (0.38) | ADORA2ASLC5A1 | |
| SCHEMBL23859566 | 0.79 | ADORA2A (0.41) | ADORA2A | |
| SCHEMBL23859205 | 0.78 | ADORA2A (0.53) | ADORA2AADORA2B | |
| SCHEMBL23858950 | 0.76 | ADORA2A (0.53) | ADORA2AADORA2B | |
| SCHEMBL23859506 | 0.76 | ADORA2A (0.41) | ADORA2AADORA2B | |
| SCHEMBL23859348 | 0.75 | ADORA2A (0.42) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552799-B2 | Triazolone compounds | NXERA PHARMA UK LIMITED (GB) | 2026-02-17 | — | — | US | claimed |
| EP-4126871-B1 | TRIAZOLONE COMPOUNDS | HEPTARES THERAPEUTICS LTD (GB) | 2024-05-08 | — | — | EP | claimed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | claimed |
| EP-4126871-A1 | TRIAZOLONE COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-02-08 | — | — | EP | claimed |
| WO-2021191380-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-09-30 | — | — | WO | claimed |
| US-12552799-B2 | Triazolone compounds | NXERA PHARMA UK LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| EP-4126871-B1 | TRIAZOLONE COMPOUNDS | HEPTARES THERAPEUTICS LTD (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| EP-4126871-A1 | TRIAZOLONE COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021191380-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885SLC5A1 626/4885ADORA2B 4/4885 |
| US-12552799-B2 | Triazolone compounds | ADORA1, ADRA2C, ADORA2A | ADORA2A 3/4885SLC5A1 449/4885ADORA2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.